Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
NCT02393755Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2015
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib in colorectal cancer (CRC) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 21 days and Progression Free Survival Rate at 18 weeks. Started May 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02393755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393755.